Zobrazeno 1 - 10
of 122
pro vyhledávání: '"M. Czejka"'
Publikováno v:
Case Reports in Oncology, Vol 6, Iss 3, Pp 602-608 (2013)
Erlotinib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor approved for the treatment of non-small cell lung cancer and when combined with gemcitabine for pancreatic cancer. Dose reduction of erlotinib in patients with sev
Externí odkaz:
https://doaj.org/article/7edb3d9f57d04eeebcca0ee2442f90af
Publikováno v:
Journal of Clinical Pharmacy and Therapeutics, 42(4), 446-453. Blackwell Publishing Ltd
What is known and objectiveMedication errors are a significant cause of morbidity and mortality especially with antineoplastic drugs, owing to their narrow therapeutic index. Gravimetric workflow software systems have the potential to reduce volumetr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d43165683af66aaf812519fb6e73e337
https://doi.org/10.1111/jcpt.12529
https://doi.org/10.1111/jcpt.12529
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Anticancer research. 31(10)
Biotransformation of irinotecan (CPT-11) into its pharmacologic active metabolite SN-38 was investigated in patients treated for advanced colorectal cancer. A dose of 180 mg/m(2) CPT-11 was administered to 6 patients by 60 min hepatic intra-arterial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8803d3b74346dc8bace640e4fdd1d8be
https://pubmed.ncbi.nlm.nih.gov/21965780
https://pubmed.ncbi.nlm.nih.gov/21965780
Publikováno v:
Anticancer research. 20(5C)
Cytoprotection of healthy cells represents a new approach in cancer chemotherapy, but a pharmacokinetic drug interaction between the cytostatic and the cytoprotectant is undesired.The purpose was to evaluate the clinical pharmacokinetics (PHK) of pac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::305c147c52ac8f42a740a85b1dd0d5c0
https://pubmed.ncbi.nlm.nih.gov/11268469
https://pubmed.ncbi.nlm.nih.gov/11268469
Publikováno v:
Die Pharmazie. 51(11)
The in vitro binding rate of epirubicin (EPR) to different plasma proteins, control serum, red blood cells and whole blood was investigated without and with the cytoprotective agent amifostine. The binding rate of EPR to plasma proteins fractions and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fb9b6502ee6c8a3d289e857382b3327c
https://pubmed.ncbi.nlm.nih.gov/9036391
https://pubmed.ncbi.nlm.nih.gov/9036391
Publikováno v:
Die Pharmazie. 50(6)
The concentration-time profile of 5-fluorouracil (5FU) in serum of patients during continuous infusion of 5FU for five days was investigated. The coadministration of each of 5 million units interferon-alpha-2b (IFN) on day 2 and 4 of the infusion cau
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3e00f6e507002adba9a7b5e2587aecfd
https://pubmed.ncbi.nlm.nih.gov/7651979
https://pubmed.ncbi.nlm.nih.gov/7651979
Publikováno v:
Arzneimittel-Forschung. 45(2)
The influence of interferon-alpha-2b (CAS 99210-65-8, IFN) on the pharmacokinetics of epirubicin (CAS 56420-45-2, EPR) was investigated in 10 patients (4 male, 6 female). EPR was injected as an i.v. bolus over 2 min in a dose of 60 mg/m2 IFN was pre-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::890cd3b319c6c6d022924f0271230ee6
https://pubmed.ncbi.nlm.nih.gov/7710452
https://pubmed.ncbi.nlm.nih.gov/7710452
Publikováno v:
Investigative ophthalmologyvisual science. 33(5)
Forty six patients received a topical application of a 0.3% norfloxacin (Zoroxin; MSD, Austria) solution into the lower fornix at different time intervals and frequencies before undergoing planned extracapsular cataract extraction. Aqueous humor was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9e65fb6b17d3fdc296941fb2e9d29d9d
https://pubmed.ncbi.nlm.nih.gov/1559771
https://pubmed.ncbi.nlm.nih.gov/1559771
Autor:
M, Czejka, J, Schüller
Publikováno v:
Archiv der Pharmazie. 325(2)
The binding of 5-fluorouracil (1) to erythrocytes and to serum proteins under in vitro conditions was investigated. The binding rate of 1 to erythrocytes is dose-independent and amounts from 16.8 to 31.7% (concentration range 1 to 20 micrograms/ml).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c879742482ca0e87cdf42b6550694a80
https://pubmed.ncbi.nlm.nih.gov/1605718
https://pubmed.ncbi.nlm.nih.gov/1605718